10764167



Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 18	Current-awareness alerts, saved answer sets, and current search transcripts to be affected by CERAB, COMPUAB, ELCOM, and SOLIDSTATE reloads
NEWS	6	NOV 30	PHAR reloaded with additional data
NEWS	7	DEC 01	LISA now available on STN
NEWS	8	DEC 09	12 databases to be removed from STN on December 31, 2004

NEWS EXPRESS	OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:30:17 ON 10 DEC 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 08:30:26 ON 10 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

Patel <12/2/2004>

STRUCTURE FILE UPDATES: 8 DEC 2004 HIGHEST RN 795251-52-4
DICTIONARY FILE UPDATES: 8 DEC 2004 HIGHEST RN 795251-52-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10764167.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 CH2,CF2

G2 H,Me,CH2,Et,n-Pr,n-Bu

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 08:30:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 578205 TO ITERATE

69.2% PROCESSED 400000 ITERATIONS 27 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.03

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 578205 TO 578205
PROJECTED ANSWERS: 27 TO 57

```
L2            27 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   155.42     155.63

FILE 'CAPLUS' ENTERED AT 08:31:03 ON 10 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 10 Dec 2004  VOL 141 ISS 25
FILE LAST UPDATED: 9 Dec 2004  (20041209/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l2
L3            3 L2

=> d l3 fbib hitstr abs total

L3   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2003:356250  CAPLUS
DN   138:348736
TI   Nicotinic acetylcholine receptor agonists in the treatment of restless
     legs syndrome
IN   Saltarelli, Mario David
PA   Pfizer Products Inc., USA
SO   PCT Int. Appl., 37 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 2003037329        A1    20030508    WO 2002-IB4379         20021021
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
```

CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			US 2001-334810P	P	20011031
			US 2001-335858P	P	20011126
US 2003134844	A1	20030717	US 2002-224055		20020820
			US 2001-334810P	P	20011031
EP 1439836	A1	20040728	EP 2002-802239		20021021
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
			US 2001-334810P	P	20011031
			US 2001-335858P	P	20011126
			WO 2002-IB4379	W	20021021
BR 2002013696	A	20041026	BR 2002-13696		20021021
			US 2001-334810P	P	20011031
			US 2001-335858P	P	20011126
			WO 2002-IB4379	W	20021021

OS MARPAT 138:348736

IT **248275-77-6 248275-90-3 248275-92-5**
248275-97-0 248275-99-2 248276-26-8
248276-28-0 248276-30-4 519165-33-4
519165-35-6 519165-36-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nicotinic agonists for treatment of restless legs syndrome)

RN 248275-77-6 CAPLUS

CN 1,5-Methano-3-benzazocine, 1,2,3,4,5,6-hexahydro-7-methoxy-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 248275-90-3 CAPLUS

CN 1,5-Methano-3-benzazocine, 1,2,3,4,5,6-hexahydro-8-methoxy-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 248275-92-5 CAPLUS

CN 1,5-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 248275-97-0 CAPLUS
CN 1,5-Methano-3-benzazocine, 8-(difluoromethoxy)-1,2,3,4,5,6-hexahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 248275-99-2 CAPLUS
CN 1,5-Methano-3-benzazocine, 8-ethoxy-1,2,3,4,5,6-hexahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 248276-26-8 CAPLUS
CN 1,5-Methano-3-benzazocine, 7-bromo-1,2,3,4,5,6-hexahydro-8-methoxy-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 248276-28-0 CAPLUS
CN 1,5-Methano-3-benzazocin-7-ol, 1,2,3,4,5,6-hexahydro-8-methoxy-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 248276-30-4 CAPLUS
CN Methanesulfonic acid, trifluoro-, 1,2,3,4,5,6-hexahydro-3-(phenylmethyl)-1,5-methano-3-benzazocin-8-yl ester (9CI) (CA INDEX NAME)



RN 519165-33-4 CAPLUS
CN 1,5-Methano-3-benzazocine, 1,2,3,4,5,6-hexahydro-9-methoxy-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 519165-35-6 CAPLUS
CN 1,5-Methano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 519165-36-7 CAPLUS
CN 1,5-Methano-3-benzazocine, 8-fluoro-1,2,3,4,5,6-hexahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



AB The invention discloses the use of nicotinic acetylcholine receptor agonists for the treatment of restless legs syndrome (RLS). The invention further discloses the use of a nicotinic acetylcholine receptor agonist in the manufacture of a medicament for the treatment of RLS. The invention also discloses a pharmaceutical composition for the treatment of RLS containing a nicotinic acetylcholine receptor agonist.
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:708745 CAPLUS
DN 131:322551
TI Aryl-fused azapolycyclic compounds as nicotine binding inhibitors
IN Coe, Jotham Wadsworth

PA Pfizer Products Inc., USA
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 9955680	A1	19991104	WO 1999-IB617		19990408
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
				US 1998-83556P	P	19980429
	CA 2330576	AA	19991104	CA 1999-2330576		19990408
				US 1998-83556P	P	19980429
				WO 1999-IB617	W	19990408
	AU 9929516	A1	19991116	AU 1999-29516		19990408
	AU 749831	B2	20020704			
				US 1998-83556P	P	19980429
				WO 1999-IB617	W	19990408
	BR 9910058	A	20001226	BR 1999-10058		19990408
				US 1998-83556P	P	19980429
				WO 1999-IB617	W	19990408
	EP 1076650	A1	20010221	EP 1999-910600		19990408
	EP 1076650	B1	20040204			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO					
				US 1998-83556P	P	19980429
				WO 1999-IB617	W	19990408
	TR 200003122	T2	20010321	TR 2000-200003122		19990408
				US 1998-83556P	P	19980429
	JP 2002513007	T2	20020508	JP 2000-545840		19990408
				US 1998-83556P	P	19980429
				WO 1999-IB617	W	19990408
	NZ 507035	A	20030530	NZ 1999-507035		19990408
				US 1998-83556P	P	19980429
				WO 1999-IB617	W	19990408
	AT 258921	E	20040215	AT 1999-910600		19990408
				US 1998-83556P	P	19980429
				WO 1999-IB617	W	19990408
	ES 2213354	T3	20040816	ES 1999-910600		19990408
				US 1998-83556P	P	19980429
	ZA 9902971	A	20001030	ZA 1999-2971		19990428
				US 1998-83556P	P	19980429
	AP 1154	A	20030327	AP 1999-1524		19990429
	W: BW, GM, GH, KE, MW, SD, UG, ZM, ZW					
				US 1998-83556P	P	19980429
				WO 1999-IB617	A	19990408
	US 6462035	B1	20021008	US 2000-582513		20000807
				US 1998-83556P	P	19980429
				WO 1999-IB617	W	19990408
	NO 2000005397	A	20001026	NO 2000-5397		20001026
				US 1998-83556P	P	19980429
				WO 1999-IB617	W	19990408

HR 2000000731	A1	20010630	HR 2000-731		20001027
			US 1998-83556P	P	19980429
			WO 1999-IB617	W	19990408
BG 104983	A	20010928	BG 2000-104983		20001124
			US 1998-83556P	P	19980429
			WO 1999-IB617	W	19990408
US 2003008890	A1	20030109	US 2002-217771		20020813
US 6706702	B2	20040316			
			US 1998-83556P	P	19980429
			WO 1999-IB617	W	19990408
			US 2000-582513	A3	20000807
US 2004167149	A1	20040826	US 2004-764167		20040123
			US 1998-83556P	P	19980429
			WO 1999-IB617	W	19990408
			US 2000-582513	A3	20000807
			US 2002-217771	A3	20020813

OS MARPAT 131:322551

IT **248276-26-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(Br/OH exchange; preparation of aryl-fused azapolycyclic compds. as inhibitors of nicotine binding to specific receptor sites)

RN 248276-26-8 CAPLUS

CN 1,5-Methano-3-benzazocine, 7-bromo-1,2,3,4,5,6-hexahydro-8-methoxy-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **248276-30-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(coupling reactions; preparation of aryl-fused azapolycyclic compds. as inhibitors of nicotine binding to specific receptor sites)

RN 248276-30-4 CAPLUS

CN Methanesulfonic acid, trifluoro-, 1,2,3,4,5,6-hexahydro-3-(phenylmethyl)-1,5-methano-3-benzazocin-8-yl ester (9CI) (CA INDEX NAME)



IT **248275-78-7P 248275-91-4P 248276-00-8P**
248276-03-1P 248276-10-0P 248276-13-3P
248276-23-5P 248276-28-0P 248276-34-8P
248276-36-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(debenzylation; preparation of aryl-fused azapolycyclic compds. as inhibitors of nicotine binding to specific receptor sites)

RN 248275-78-7 CAPLUS
CN 1,5-Methano-3-benzazocine, 1,2,3,4,5,6-hexahydro-7-methoxy-3-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 248275-91-4 CAPLUS
CN 1,5-Methano-3-benzazocine, 1,2,3,4,5,6-hexahydro-8-methoxy-3-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 248276-00-8 CAPLUS
CN 1,5-Methano-3-benzazocine, 8-ethoxy-1,2,3,4,5,6-hexahydro-3-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 248276-03-1 CAPLUS
CN 1,5-Methano-3-benzazocine, 1,2,3,4,5,6-hexahydro-8-(1-methylethoxy)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 248276-10-0 CAPLUS
CN 1,5-Methano-3-benzazocine, 1,2,3,4,5,6-hexahydro-9-methoxy-3-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 248276-13-3 CAPLUS
CN 1,5-Methano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 248276-23-5 CAPLUS
CN 1,5-Methano-3-benzazocine, 8-fluoro-1,2,3,4,5,6-hexahydro-3-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 248276-28-0 CAPLUS
CN 1,5-Methano-3-benzazocin-7-ol, 1,2,3,4,5,6-hexahydro-8-methoxy-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 248276-34-8 CAPLUS
CN 1,5-Methano-3-benzazocine-8-carboxylic acid, 1,2,3,4,5,6-hexahydro-3-(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 248276-36-0 CAPLUS
CN 1,5-Methano-3-benzazocine-8-methanol, 1,2,3,4,5,6-hexahydro-α,α-dimethyl-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **248275-97-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(demethylation; preparation of aryl-fused azapolycyclic compds. as inhibitors of nicotine binding to specific receptor sites)
RN 248275-97-0 CAPLUS
CN 1,5-Methano-3-benzazocine, 8-(difluoromethoxy)-1,2,3,4,5,6-hexahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **248276-27-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(oxidation; preparation of aryl-fused azapolycyclic compds. as inhibitors of nicotine binding to specific receptor sites)
RN 248276-27-9 CAPLUS
CN Boronic acid, [1,2,3,4,5,6-hexahydro-8-methoxy-3-(phenylmethyl)-1,5-methano-3-benzazocin-7-yl]- (9CI) (CA INDEX NAME)



IT **248275-77-6P 248275-93-6P 248275-99-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl-fused azapolycyclic compds. as inhibitors of nicotine binding to specific receptor sites)
RN 248275-77-6 CAPLUS
CN 1,5-Methano-3-benzazocine, 1,2,3,4,5,6-hexahydro-7-methoxy-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 248275-93-6 CAPLUS
CN 1,5-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-3-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



RN 248275-99-2 CAPLUS
CN 1,5-Methano-3-benzazocine, 8-ethoxy-1,2,3,4,5,6-hexahydro-3-(phenylmethyl)-

(9CI) (CA INDEX NAME)



IT **248276-31-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aryl-fused azapolycyclic compds. as inhibitors of nicotine binding to specific receptor sites)
RN 248276-31-5 CAPLUS
CN 1,5-Methano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(phenylmethyl)-8-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT **248275-90-3P 248275-92-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(reactions; preparation of aryl-fused azapolycyclic compds. as inhibitors of nicotine binding to specific receptor sites)
RN 248275-90-3 CAPLUS
CN 1,5-Methano-3-benzazocine, 1,2,3,4,5,6-hexahydro-8-methoxy-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 248275-92-5 CAPLUS
CN 1,5-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-3-(phenylmethyl)-(9CI) (CA INDEX NAME)



GI



I



II



III



IV



V

AB Compds. of formula (I) and their pharmaceutically acceptable salts, wherein: Z = CH2, CO, CF2; R1 = e.g., H, C1-6-alkyl, unconjugated C3-6-alkenyl, benzyl; R2, R3 are independently, e.g., H, C2-6-alkenyl, C2-6-alkynyl, hydroxy, nitro, amino, halo, cyano, were prepared as nicotine binding inhibitors (IC50 < 10μM). Thus, e.g., metalation/addition reaction of 1,2-difluoro-4-methoxybenzene with cyclopent-3-enecarboxaldehyde afforded the methanol II; reduction, demethylation, and sulfonylation afforded triflate III; Heck cyclization to IV was followed by osmylation/oxidation to the diol; the latter was converted to title compound V via oxidative cleavage/reductive amination.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:528299 CAPLUS
DN 127:109166
TI Synthesis of a New Tyrosine Analog Having χ1 and χ2 Angles Constrained to Values Observed for an SH2 Domain-Bound Phosphotyrosyl Residue
AU Ye, Bin; Yao, Zhu-Jun; Burke, Terrence R., Jr.
CS Laboratory of Medicinal Chemistry Division of Basic Sciences National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
SO Journal of Organic Chemistry (1997), 62(16), 5428-5431
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 127:109166
IT **192212-94-5P 192212-95-6P 192212-96-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation of constrained tyrosine analog with χ1 and χ2 values close to SH2 domain-bound phosphotyrosyl residues)

RN 192212-94-5 CAPLUS
CN 1,5-Methano-3-benzazocine-2,11(1H)-dione, 3-[(2,4-dimethoxyphenyl)methyl]-3,4,5,6-tetrahydro-8-methoxy-1-methyl- (9CI) (CA INDEX NAME)



RN 192212-95-6 CAPLUS
CN 1,5-Methano-3-benzazocin-2(1H)-one, 3-[(2,4-dimethoxyphenyl)methyl]-3,4,5,6-tetrahydro-8-methoxy-1-methyl- (9CI) (CA INDEX NAME)



RN 192212-96-7 CAPLUS
CN 1,5-Methano-3-benzazocine-2-carbonitrile, 3-[(2,4-dimethoxyphenyl)methyl]-1,2,3,4,5,6-hexahydro-8-methoxy-1-methyl-, (1α,2α,5α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **192212-97-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of constrained tyrosine analog with χ1 and χ2 values close to SH2 domain-bound phosphotyrosyl residues)

RN 192212-97-8 CAPLUS
CN 1,5-Methano-3-benzazocine, 3-[(2,4-dimethoxyphenyl)methyl]-1,2,3,4,5,6-hexahydro-8-methoxy-1-methyl- (9CI) (CA INDEX NAME)



GI



I

AB Synthesis is reported of new tricyclic amino acid I (R = H), which contains within its structure the elements of a tyrosine moiety having χ1 and χ2 angles (168° and -95°, resp.) constrained to values observed for a phosphotyrosyl (pTyr) residue bound to the 56lck SH2 domain (χ1 and χ2 values of 163° and -94°, resp.). Addnl., the ϕ angle of I (R = acyl) correlates well with the ϕ angle of the SH2 domain-bound pTyr residue. I (R = H) represents a unique, highly constrained amino acid which may be of value in signal transduction studies.